RNA Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

Prezzo

$12.84

Capitalizzazione di Mercato

$10.91B

P/E (TTM)

-14.5

EPS (TTM)

$-4.97

Ricavi (TTM)

$19M

Rendimento div.

—

ROE

-47.5%

D/E Debito/Patrimonio

—

Intervallo 52 sett.

$12 – $73

RNA Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione

Performance decennale Andamento di ricavi, utile netto, margini e EPS

Ricavi e Utile Netto $19M

2018-12-31 → 2025-12-31

EPS $-4.97

2020-12-31 → 2025-12-31

Flusso di cassa libero $-664M

2020-12-31 → 2025-12-31

Margini -3650.4%

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Metrica

Tendenza 5 anni

RNA

Mediana dei peer

P/E (TTM)

-14.5

2.4

P/S (TTM)

581.5

15.2

P/B

6.5

1.4

Price / FCF (Prezzo / FCF)

-16.4

—

Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC

Metrica

Tendenza 5 anni

RNA

Mediana dei peer

Operating Margin (Margine Operativo)

-3977.3%

—

Net Profit Margin (Margine di Profitto Netto)

-3650.4%

-946.2%

ROA

-38.9%

-52.8%

ROE

-47.5%

-60.2%

ROIC

-44.2%

—

Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio

Metrica

Tendenza 5 anni

RNA

Mediana dei peer

Current Ratio (Rapporto corrente)

9.2

7.4

Quick Ratio

2.0

—

Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y

Metrica

Tendenza 5 anni

RNA

Mediana dei peer

Revenue YoY (Ricavi YoY)

72.1%

—

Revenue CAGR 3Y (CAGR Ricavi 3Y)

26.7%

—

Revenue CAGR 5Y (CAGR Ricavi 5Y)

22.5%

—

Metriche per Azione EPS, valore contabile per azione, flusso di cassa per azione, dividendo per azione

Metrica

Tendenza 5 anni

RNA

Mediana dei peer

EPS (Diluted) (EPS (Diluito))

$-4.97

—

Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti

Metrica

Tendenza 5 anni

RNA

Mediana dei peer

RNA Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

COMPRA 5 analisti

Acquisto forte 1 20,0%
Compra 3 60,0%
Mantieni 1 20,0%
Vendi 0 0,0%
Vendita forte 0 0,0%

Target Price a 12 Mesi

2 analisti · 2026-05-20

Basso $25.00

Alto $25.00

Target mediano $25.00 +94,8%

Target medio $25.00 +94,8%

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

Sorpresa media

0.09%

Periodo	EPS Actual	EPS Stimato	Sorpresa
31 Marzo 2026	$-0.97	$-1.06	0.09%

Confronto tra pari Metriche chiave rispetto ai pari del settore

Ticker	Capitalizzazione di Mercato	P/E	Rev YoY	Margine Netto	ROE	Margine lordo
RNA	$10.91B	-14.5	72.1%	-3650.4%	-47.5%	—
FHTX	$306M	-4.6	36.8%	-240.3%	80.2%	—
NERV	$174M	-0.1	—	—	339.5%	—
FATE	$113M	-0.9	-51.2%	-2051.1%	-58.2%	—
WHWK	$114M	-7.3	-72.5%	-288.3%	-13.4%	—
IKT	$270M	-4.2	111.0%	-1299.0%	-38.2%	—
KROS	$398M	8.9	—	35.7%	17.2%	—
BDTX	$139M	6.2	—	31.9%	18.3%	—
VYGR	$232M	-1.9	-49.5%	-296.5%	-54.4%	—
UNCY	$128M	-3.5	-29.0%	—	-113.9%	—

Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario

Conto Economico 15

Dati annuali Conto Economico per RNA
Metrica	2025	2024	2023	2022	2022	2021	2020	2019
Revenue	$19M	$11M	$10M	$9M	·	$9M	$7M	$2M
R&D Expense	$559M	$304M	$191M	$150M	·	$101M	$38M	$15M
SG&A Expense	$206M	$86M	$54M	$38M	·	$26M	$13M	$5M
Operating Expenses	$765M	$390M	$245M	$188M	·	$127M	$51M	$20M
Operating Income	$-746M	$-379M	$-236M	$-179M	·	$-118M	$-44M	$-17M
Interest Expense	·	·	·	$0	·	$0	$209.0K	$7M
Other Non-op	$-2M	$-248.0K	$-594.0K	$-57.0K	·	$-62.0K	$-75.0K	$0
Pretax Income	$-685M	$-322M	$-212M	·	·	·	·	·
Income Tax	$0	$0	$0	$0	·	$0	$0	$0
Net Income	$-685M	$-322M	$-212M	$-174M	·	$-118M	$-44M	$-25M
EPS (Basic)	$-4.97	$-2.89	$-2.91	$-3.34	·	$-2.85	$-2.05	·
EPS (Diluted)	$-4.97	$-2.89	$-2.91	$-3.34	·	$-2.85	$-2.05	·
Shares (Basic)	137,710,000	111,582,000	73,012,000	52,162,000	·	41,428,000	21,663,000	·
Shares (Diluted)	137,710,000	111,582,000	73,012,000	52,162,000	·	41,428,000	21,663,000	·
EBITDA	$-746M	$-379M	$-236M	$-179M	·	$-118M	$-44M	·

Stato Patrimoniale 24

Dati annuali Stato Patrimoniale per RNA
Metrica	2025	2024	2023	2022	2022	2021	2020	2019
Cash & Equivalents	$383M	$220M	$185M	$340M	·	$320M	$321M	$95M
Short-term Investments	·	·	·	·	·	$85M	$7M	·
Receivables	·	$0	$1M	$2M	·	·	·	·
Prepaid Expense	$102M	$41M	$16M	$12M	·	$6M	·	·
Other Current Assets	$53M	$19M	·	$2M	·	·	·	·
Current Assets	$1.80B	$1.54B	$611M	$623M	·	$411M	$332M	$96M
PP&E (Net)	$23M	$13M	$8M	$6M	·	$5M	$1M	$631.0K
PP&E (Gross)	$35M	$21M	$14M	$9M	·	$7M	$3M	$2M
Accum. Depreciation	$12M	$8M	$5M	$3M	·	$2M	$2M	$2M
Other Non-current Assets	$82M	$521.0K	$301.0K	$598.0K	·	$599.0K	$47.0K	$600.0K
Total Assets	$1.96B	$1.56B	$629M	$639M	·	$428M	$334M	$97M
Accounts Payable	$12M	$8M	$9M	$5M	·	$3M	$8M	$2M
Current Liabilities	$195M	$98M	$81M	$52M	·	$30M	$15M	$10M
Capital Leases	$45M	$3M	$6M	$8M	·	$10M	$938.0K	$393.0K
Other Non-current Liabilities	·	·	·	·	·	·	·	$45.0K
Total Liabilities	$269M	$139M	$128M	$61M	·	$46M	$28M	$28M
Long-term Debt	·	·	·	·	·	·	·	$5M
Common Stock	$15.0K	$12.0K	$8.0K	$7.0K	·	$5.0K	$4.0K	$0
Paid-in Capital	·	·	·	$939M	·	$566M	$373M	$-43M
Retained Earnings	$-1.58B	$-893M	$-571M	$-359M	·	$-185M	$-67M	$-22M
AOCI	$3M	$3M	$125.0K	$-3M	·	$-187.0K	$-5.0K	·
Stockholders' Equity	$1.69B	$1.42B	$501M	$578M	$374M	$381M	$306M	$-65M
Liabilities + Equity	$1.96B	$1.56B	$629M	$639M	·	$428M	$334M	$97M
Shares Outstanding	151,205,000	119,893,000	79,275,000	69,768,000	52,081,000	47,754,000	37,569,000	2,989,000

Flusso di cassa 10

Dati annuali Flusso di cassa per RNA
Metrica	2025	2024	2023	2022	2022	2021	2020	2019
Stock-based Comp	$98M	$51M	$38M	$27M	·	$17M	$4M	$406.0K
Operating Cash Flow	$-650M	$-301M	$-119M	$-136M	·	$-95M	$-37M	$2M
CapEx	$13M	$7M	$4M	$3M	·	$4M	$1M	$235.0K
Investing Cash Flow	$-38M	$-854M	$-130M	$-190M	·	$-83M	$-8M	$-235.0K
Net Debt Issued	·	·	·	$0	·	$0	$-5M	·
Stock Issued	$837M	$762M	$61M	$345M	$82M	$175M	$274M	·
Net Stock Activity	$837M	$762M	$61M	$345M	$82M	$20M	·	·
Financing Cash Flow	$851M	$1.19B	$94M	$346M	·	$176M	$272M	$89M
Net Change in Cash	$163M	$37M	$-155M	$20M	·	$-1M	$227M	$91M
Free Cash Flow	$-664M	$-308M	$-123M	$-139M	·	$-99M	$-38M	·

Redditività 7

Dati annuali Redditività per RNA
Metrica	2025	2024	2023	2022	2022	2021	2020	2019
Operating Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	·	-1265.8%	-652.4%	·
Net Margin	-3650.4%	-2957.7%	-2219.9%	-1886.3%	·	-1265.4%	-653.5%	·
Pretax Margin	-3650.4%	·	·	·	·	·	·	·
EBITDA Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	·	-1265.8%	-652.4%	·
ROA	-38.9%	-29.4%	-33.5%	-32.6%	·	-31.0%	-20.6%	·
ROE	-47.5%	-22.0%	-41.7%	-36.4%	·	-30.4%	-14.2%	·
ROIC	-44.2%	·	·	·	·	·	·	·

Liquidità e Solvibilità 3

Dati annuali Liquidità e Solvibilità per RNA
Metrica	2025	2024	2023	2022	2022	2021	2020	2019
Current Ratio	9.2	15.7	7.6	12.0	·	13.9	22.7	·
Quick Ratio	2.0	2.2	2.3	6.6	·	13.7	22.5	·
Interest Coverage	·	·	·	·	·	·	-211.9	·

Efficienza 2

Dati annuali Efficienza per RNA
Metrica	Tendenza	2025	2024	2023	2022	2022	2021	2020	2019
Asset Turnover		0.0	0.0	0.0	0.0	·	0.0	0.0	·
Receivables Turnover		·	19.7	5.5	·	·	·	·	·

Per Azione 5

Dati annuali Per Azione per RNA
Metrica	2025	2024	2023	2022	2022	2021	2020	2019
Book Value / Share	$11.17	$11.89	$6.32	$8.29	·	$7.99	$8.15	·
Revenue / Share	$0.14	$0.10	$0.13	$0.18	·	·	·	·
Cash Flow / Share	$-4.72	$-2.70	$-1.63	$-2.61	·	·	·	·
Cash / Share	$2.53	$1.83	$2.33	$4.88	·	$6.71	$8.56	·
EPS (TTM)	$-4.97	$-2.89	$-2.91	$-3.34	$-3.01	$-2.85	$-2.05	·

Tassi di Crescita 3

Dati annuali Tassi di Crescita per RNA
Metrica	2025	2024	2023	2022	2022	2021	2020	2019
Revenue YoY	72.1%	14.0%	3.6%	-1.1%	·	37.4%	·	·
Revenue CAGR 3Y	26.7%	5.3%	12.1%	·	·	·	·	·
Revenue CAGR 5Y	22.5%	·	·	·	·	·	·	·

Valutazione (TTM) 10

Dati annuali Valutazione (TTM) per RNA
Metrica	2025	2024	2023	2022	2022	2021	2020	2019
Revenue TTM	$19M	$11M	$10M	$9M	$9M	$9M	$7M	·
Net Income TTM	$-685M	$-322M	$-212M	$-174M	$-136M	$-118M	$-44M	·
Market Cap	$10.91B	$3.49B	$717M	$1.55B	·	$1.14B	$959M	·
P/E	-14.5	-10.1	-3.1	-6.6	-4.8	-8.3	-12.4	·
P/S	581.5	319.9	75.0	167.8	·	121.7	141.3	·
P/B	6.5	2.4	1.4	2.7	·	3.0	3.1	·
P / Tangible Book	6.5	2.4	1.4	2.7	·	3.0	3.1	·
P / Cash Flow	-16.8	-11.6	-6.0	-11.4	·	-12.0	-25.8	·
P / FCF	-16.4	-11.3	-5.8	-11.1	·	-11.5	-25.1	·
Earnings Yield	-6.9%	-9.9%	-32.1%	-15.0%	-20.7%	-12.0%	-8.0%	·

Conto Economico 12

Dati trimestrali Conto Economico per RNA
Metrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue	$860.0K	$12M	$4M	$2M	$3M	$2M	$2M	$4M	$2M	$3M	$2M	$2M	$3M	$2M	$2M	$2M
R&D Expense	$167M	$155M	$138M	$99M	$96M	$77M	$64M	$67M	$53M	$48M	$43M	$48M	$46M	$37M	$40M	$28M
SG&A Expense	$89M	$46M	$37M	$34M	$28M	$23M	$21M	$14M	$16M	$14M	$12M	$12M	$10M	$10M	$9M	$9M
Operating Expenses	$255M	$201M	$175M	$133M	$124M	$100M	$85M	$81M	$69M	$61M	$55M	$60M	$56M	$47M	$48M	$36M
Operating Income	$-254M	$-189M	$-171M	$-132M	$-121M	$-98M	$-83M	$-77M	$-67M	$-59M	$-53M	$-58M	$-53M	$-45M	$-46M	$-34M
Other Non-op	$-477.0K	$-380.0K	$-651.0K	$-435.0K	$201.0K	$-232.0K	$-116.0K	$-101.0K	$-105.0K	$-13.0K	$-162.0K	$-314.0K	$-18.0K	$-12.0K	$-2.0K	$-25.0K
Net Income	$-237M	$-174M	$-157M	$-116M	$-102M	$-80M	$-71M	$-69M	$-60M	$-52M	$-47M	$-52M	$-50M	$-44M	$-46M	$-34M
EPS (Basic)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
EPS (Diluted)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
Shares (Basic)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
Shares (Diluted)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
EBITDA	·	$-189M	$-171M	$-132M	·	$-98M	$-83M	$-77M	·	$-59M	$-53M	$-58M	·	$-45M	·	$-34M

Stato Patrimoniale 21

Dati trimestrali Stato Patrimoniale per RNA
Metrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Cash & Equivalents	$383M	$350M	$244M	$254M	$220M	$370M	$576M	$471M	·	$86M	$154M	$119M	·	$144M	$125M	$139M
Short-term Investments	·	·	·	·	·	·	·	·	·	·	·	·	·	$262M	$273M	$258M
Receivables	·	·	·	·	·	$0	$0	$2M	·	·	$1M	·	·	·	·	·
Prepaid Expense	$102M	$90M	$67M	$55M	$41M	$33M	$30M	$19M	·	·	$11M	·	·	·	·	·
Other Current Assets	$53M	$60M	$43M	·	$19M	·	·	·	·	·	$6M	·	·	·	·	·
Current Assets	$1.80B	$1.97B	$1.25B	$1.43B	$1.54B	$1.62B	$1.33B	$934M	·	$555M	$595M	$597M	·	$414M	$404M	$405M
PP&E (Net)	$23M	$22M	$21M	$16M	$13M	$9M	$8M	$9M	·	$8M	$8M	$8M	·	$6M	$6M	$5M
PP&E (Gross)	$35M	$32M	$30M	$24M	$21M	$17M	$15M	$15M	·	$13M	$12M	$11M	·	$9M	$9M	$7M
Accum. Depreciation	$12M	$10M	$10M	$9M	$8M	$7M	$7M	$6M	·	$5M	$4M	$4M	·	$3M	$2M	$2M
Other Non-current Assets	$82M	$91M	$91M	$739.0K	$521.0K	$318.0K	$364.0K	$425.0K	·	$344.0K	$424.0K	$474.0K	·	$523.0K	$415.0K	$548.0K
Total Assets	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Accounts Payable	$12M	$10M	$4M	$7M	$8M	$8M	$9M	$2M	·	$6M	$6M	$4M	·	$26M	$21M	$19M
Current Liabilities	$195M	$170M	$135M	$85M	$98M	$91M	$84M	$75M	·	$49M	$45M	$48M	·	$43M	$34M	$31M
Capital Leases	$45M	$46M	$1M	$2M	$3M	$4M	$5M	$5M	·	$7M	$6M	$7M	·	$8M	$9M	$9M
Total Liabilities	$269M	$248M	$176M	$130M	$139M	$137M	$126M	$121M	·	$56M	$52M	$55M	·	$54M	$46M	$45M
Common Stock	$15.0K	$15.0K	$12.0K	$12.0K	$12.0K	$12.0K	$11.0K	$10.0K	·	$7.0K	$7.0K	$7.0K	·	$5.0K	$5.0K	$5.0K
Retained Earnings	$-1.58B	$-1.34B	$-1.17B	$-1.01B	$-893M	$-791M	$-710M	$-640M	·	$-510M	$-458M	$-411M	·	$-308M	$-264M	$-219M
AOCI	$3M	$2M	$2M	$3M	$3M	$7M	$-453.0K	$-464.0K	·	$-2M	$-3M	$-2M	·	$-3M	$-3M	$-2M
Stockholders' Equity	$1.69B	$1.89B	$1.19B	$1.33B	$1.42B	$1.50B	$1.22B	$831M	$501M	$517M	$559M	$559M	$578M	$377M	$374M	$376M
Liabilities + Equity	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Shares Outstanding	151,205,000	146,771,000	120,778,000	120,512,000	119,893,000	118,900,000	109,266,000	95,594,000	79,275,000	74,101,000	74,070,000	70,813,000	69,768,000	54,446,000	52,081,000	49,281,000

Flusso di cassa 9

Dati trimestrali Flusso di cassa per RNA
Metrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Stock-based Comp	$43M	$19M	$18M	$18M	$14M	$14M	$13M	$10M	$10M	$10M	$9M	$9M	$7M	$7M	$7M	$6M
Operating Cash Flow	$-170M	$-156M	$-200M	$-125M	$-100M	$-66M	$-65M	$-70M	$17M	$-37M	$-50M	$-49M	$-39M	$-32M	$-36M	$-30M
CapEx	$6M	$712.0K	$3M	$4M	$4M	$2M	$531.0K	$915.0K	$863.0K	$923.0K	$622.0K	$2M	$850.0K	$-107.0K	$1M	$758.0K
Investing Cash Flow	$207M	$-588M	$185M	$157M	$-64M	$-482M	$-275M	$-33M	$51M	$-31M	$46M	$-196M	$-8M	$11M	$-18M	$-175M
Stock Issued	$-538.0K	$837M	$0	$0	$-500.0K	$324M	$433M	$6M	$0	$0	$38M	$22M	$243M	$39M	$38M	$24M
Net Stock Activity	·	·	·	$0	·	·	·	$6M	·	·	·	$22M	·	·	·	$24M
Financing Cash Flow	$-5M	$850M	$4M	$2M	$14M	$342M	$447M	$389M	$32M	$40.0K	$39M	$23M	$244M	$40M	$39M	$24M
Net Change in Cash	$32M	$106M	$-10M	$34M	$-150M	$-206M	$107M	$286M	$99M	$-68M	$35M	$-222M	$197M	$19M	$-14M	$-181M
Free Cash Flow	·	·	·	$-129M	·	·	·	$-71M	·	·	·	$-51M	·	·	·	$-30M

Redditività 5

Dati trimestrali Redditività per RNA
Metrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Operating Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
Net Margin	·	-1398.3%	-4089.3%	-7360.0%	·	-3441.7%	-3461.8%	-1943.4%	·	-1858.0%	-2030.4%	-2346.3%	·	-1756.6%	·	-1907.2%
EBITDA Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
ROA	·	-9.2%	-11.6%	-9.6%	·	-7.3%	-7.2%	-8.8%	·	-10.4%	-9.1%	-10.1%	·	-10.2%	·	-9.3%
ROE	·	-10.3%	-13.0%	-10.7%	·	-8.0%	-8.0%	-9.9%	·	-11.7%	-10.1%	-11.2%	·	-11.3%	·	-10.3%

Liquidità e Solvibilità 2

Dati trimestrali Liquidità e Solvibilità per RNA
Metrica	Tendenza	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Current Ratio		·	11.6	9.3	16.9	·	17.8	15.8	12.5	·	11.4	13.1	12.4	·	9.7	·	13.1
Quick Ratio		·	2.1	1.8	3.0	·	4.1	6.8	6.3	·	1.8	3.4	2.5	·	9.5	·	12.8

Efficienza 2

Dati trimestrali Efficienza per RNA
Metrica	Tendenza	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Asset Turnover		·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	·	0.0
Receivables Turnover		·	·	·	·	·	·	3.5	4.5	·	·	3.9	·	·	·	·	·

Per Azione 5

Dati trimestrali Per Azione per RNA
Metrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Book Value / Share	·	$12.85	$9.87	$11.03	·	$12.64	$11.17	$8.69	·	$6.98	$7.55	$7.89	·	$6.92	·	$7.62
Revenue / Share	·	$0.09	$0.03	$0.01	·	$0.02	$0.02	$0.04	·	$0.04	$0.03	$0.03	·	$0.05	·	·
Cash Flow / Share	·	·	·	$-0.97	·	·	·	$-0.81	·	·	·	$-0.70	·	·	·	·
Cash / Share	·	$2.39	$2.02	$2.11	·	$3.11	$5.27	$4.93	·	$1.16	$2.08	$1.68	·	$2.64	·	$2.83
EPS (TTM)	·	$-4.03	$-3.41	$-2.99	·	$-2.80	$-2.81	$-2.90	·	$-2.93	$-3.14	$-3.19	·	$-3.13	·	·

Valutazione (TTM) 10

Dati trimestrali Valutazione (TTM) per RNA
Metrica	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue TTM	·	$20M	$10M	$9M	·	$11M	$11M	$11M	·	$10M	$9M	$9M	·	$9M	·	$9M
Net Income TTM	·	$-528M	$-424M	$-336M	·	$-272M	$-239M	$-221M	·	$-195M	$-189M	$-176M	·	$-153M	·	$-114M
Market Cap	·	$6.39B	$3.43B	$3.56B	·	$5.46B	$4.46B	$2.44B	·	$473M	$821M	$1.09B	·	$889M	·	$910M
P/E	·	-10.8	-8.3	-9.9	·	-16.4	-14.5	-8.8	·	-2.2	-3.5	-4.8	·	-5.2	·	·
P/S	·	316.1	350.0	374.6	·	508.4	416.3	223.6	·	48.0	89.2	125.1	·	103.2	·	98.2
P/B	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Tangible Book	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Cash Flow	·	·	·	-28.5	·	·	·	-34.7	·	·	·	-22.2	·	·	·	-30.8
P / FCF	·	·	·	-27.7	·	·	·	-34.2	·	·	·	-21.4	·	·	·	-30.0
Earnings Yield	·	-9.2%	-12.0%	-10.1%	·	-6.1%	-6.9%	-11.4%	·	-45.9%	-28.3%	-20.8%	·	-19.2%	·	·

Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni

Conto Economico

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Ricavi	$19M	$11M	$10M	$9M	$9M
Margine Operativo %	-3977.3%	-3477.4%	-2464.4%	-1939.6%	-1265.8%
Utile netto	$-685M	$-322M	$-212M	$-174M	$-118M
EPS Diluito	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85

Stato Patrimoniale

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Rapporto corrente	9.2	15.7	7.6	12.0	13.9
Quick Ratio	2.0	2.2	2.3	6.6	13.7

Flusso di cassa

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Flusso di cassa libero	$-664M	$-308M	$-123M	$-139M	$-99M

Ultime notizie Notizie recenti che menzionano questa società

CureVac fa causa a Moderna per violazione di brevetti sui vaccini COVID-19 Yahoo Finance · 3 settimane, 3 giorni fa

Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi

📊

Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.

La tua selezione è salvata e ti segue su tutti i ticker.

RNA Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

RNA Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione

Medie mobili e sovrapposizioni

Volume

Oscillatori

Momentum e tendenza

Performance decennale Andamento di ricavi, utile netto, margini e EPS

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC

Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio

Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y

Metriche per Azione EPS, valore contabile per azione, flusso di cassa per azione, dividendo per azione

Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti

RNA Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

Target Price a 12 Mesi

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

Confronto tra pari Metriche chiave rispetto ai pari del settore

Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario

Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni

Ultime notizie Notizie recenti che menzionano questa società

Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi